COMPARING SURVIVAL EXTRAPOLATION OUTCOMES USING DIFFERENT NETWORK META-ANALYSES (NMA) METHODS: AN APPLICATION IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC) TREATED WITH IMMUNOTHERAPY (IO) BASED COMBINATIONS

被引：0
|
作者：
Krol, F. [1 ]
Depalma, S. [1 ]
El Alili, H. [1 ]
Verhoek, A. [1 ]
van Beekhuizen, S. [1 ]
Heeg, B. [1 ]
机构：
[1] Cytel Inc, Rotterdam, ZH, Netherlands
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
MSR50
引用
收藏
页码：S359 / S359
页数：1
相关论文
共 50 条
  • [31] Interleukin-2 (IL-2)-based immunotherapy for the treatment of metastatic renal cell carcinoma (mRCC): An analysis of 422 consecutive patients treated between 1999 and 2008.
    Donskov, F.
    Jensen, H. K.
    Jeppesen, A. N.
    Fode, K.
    Schmidt, H.
    Agerbaek, M.
    Broendum, L.
    von der Maase, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [32] Association between baseline radiological tumor burden (BRTB) and outcomes in metastatic clear cell renal cell carcinoma (mccRCC) treated with first line (1L) immunotherapy (IO)-based regimens
    Nawfal, R.
    Semaan, K.
    Eid, M.
    Paul, M.
    Saliby, R. M.
    Chehade, R. El Hajj
    Machaalani, M.
    Saad, E.
    Phillips, N.
    Canniff, J.
    Vasseur, D.
    El Zarif, T.
    Yekeduz, E.
    Sun, M.
    Baca, S.
    Braun, D. A.
    Xie, W.
    Krajewski, K.
    Choueiri, T. K.
    ANNALS OF ONCOLOGY, 2024, 35 : S1022 - S1023
  • [33] THE IMPACT OF CLINICAL HETEROGENEITY ON CONDUCTING NETWORK META-ANALYSES FOR PROGRESSION-FREE SURVIVAL OF PREVIOUSLY UNTREATED INTERMEDIATE- OR POOR-RISK ADVANCED/METASTATIC RENAL CELL CARCINOMA THERAPIES
    Szabo, N.
    Grevinga, M.
    Malcolm, B.
    Kurt, M.
    Ejzykowicz, F.
    Chun, D. S.
    May, J.
    Kroep, S.
    VALUE IN HEALTH, 2020, 23 : S750 - S750
  • [34] Acquired hypothyroidism as a predictive marker of outcome in patients with metastatic renal cell carcinoma (mRCC) treated with tyrosine-kinase inhibitors (TKIs): A literature-based meta-analysis
    Nearchou, Andreas Demetrios
    Valachis, Antonis
    Lind, Pehr A.
    Akre, Olof
    Sandstrom, Per
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [35] Acquired hypothyroidism as a predictive marker of outcome in patients with metastatic renal cell carcinoma (mRCC) treated with tyrosine-kinase inhibitors (TKIs): A literature-based meta-analysis.
    Nearchou, Andreas Demetrios
    Valachis, Antonis
    Lind, Pehr
    Akre, Olof
    Sandstrom, Per
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [36] Impact of Synchronous versus Metachronous Metastasis on Outcomes in Patients with Metastatic Renal Cell Carcinoma Treated with First-line Immune Checkpoint Inhibitor-based Combinations
    Gebrael, Georges
    Meza, Luis
    Li, Xiaochen
    Zengin, Zeynep
    Sayegh, Nicolas
    Ebrahimi, Hedyeh
    Tripathi, Nishita
    Castro, Daniela
    Mercier, Benjamin
    Barragan-Carrillo, Regina
    Li, Haoran
    Chehrazi-Raffle, Alexander
    Swami, Umang
    Tripathi, Abhishek
    Agarwal, Neeraj
    Maughan, Benjamin L.
    Pal, Sumanta K.
    EUROPEAN UROLOGY FOCUS, 2024, 10 (05): : 812 - 817
  • [37] Progression-free survival after second line of therapy (PFS-2) for metastatic clear cell renal cell carcinoma (ccRCC) in patients treated with first-line immunotherapy combinations.
    Fitzgerald, Kelly N.
    Duzgol, Cihan
    Knezevic, Andrea
    Shapnik, Natalie
    Kotecha, Ritesh
    Aggen, David Henry
    Carlo, Maria Isabel
    Shah, Neil J.
    Voss, Martin H.
    Feldman, Darren R.
    Motzer, Robert J.
    Lee, Chung-Han
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [38] Overall survival among metastatic renal cell carcinoma (MRCC) patients corrected for crossover using a rank preserving structural failure time (RPSFT) model: analyses from the everolimus phase III trial
    Korhonen, P.
    Haas, T.
    Zuber, E.
    Kay, A.
    Lebwohl, D.
    Motzer, R.
    EJC SUPPLEMENTS, 2009, 7 (02): : 440 - 440
  • [39] IO-Synthesise RCC: Analysis of real-world (RW) health-related quality of life (HRQoL) outcomes with nivolumab for previously treated metastatic renal cell carcinoma (mRCC) using pooled data from France and Germany
    Mouillet, G.
    Bedke, J.
    Albiges, L.
    Barthelemy, P.
    Escudier, B.
    Gruenwald, V.
    Ivanyi, P.
    Mueller-Huesmann, H.
    Vano, Y-A.
    von der Heyde, E.
    Ejzykowicz, F.
    Brellier, F.
    Herber, M.
    Quentric, C.
    Bennett, B. M.
    Nere, S.
    Autengruber, A.
    Thiery-Vuillemin, A.
    Grimm, M-O.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1212 - S1213
  • [40] Impact of Time to Metastasis (Synchronous vs. Metachronous) on Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with First Line Immune-Checkpoint Inhibitors (ICI)-based Combinations
    Meza, Luis
    Li, Xiaochen
    Zengin, Zeynep
    Sayegh, Nicolas
    Ebrahimi, Hedyeh
    Tripathi, Nishita
    Castro, Daniela
    Mercier, Benjamin
    Barragan-Carrillo, Regina
    Li, Haoran
    Chehrazi-Raffle, Alexander
    Swami, Umang
    Tripathi, Abishek
    Agarwal, Neeraj
    Maughan, Benjamin L.
    Pal, Sumanta K.
    ONCOLOGIST, 2023, 28 : S9 - S10
12345